Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Head & Neck|July 10, 2001
Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysisN Magné, P Y Marcy, E Chamorey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patientsX Pivot, E Chamorey, E Guardiola, et al.
Annals of the New York Academy of Sciences|November 21, 2000
Immunomodulating activity of MDMAR Pacifici, P Zuccaro, M Farré, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2003
Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearanceM C Etienne, F Leger, X Pivot, et al.
Gynecologic Oncology|September 24, 2009
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II studyF Joly, T Petit, P Pautier, et al.
Oncology|September 28, 2001
Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trialsX Pivot, C Niyikiza, G Poissonnet, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2000
An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemiaX Pivot, E Guardiola, M Etienne, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapyN Magné, X Pivot, R J Bensadoun, et al.
Oncology|January 11, 2001
Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neckX Pivot, L Cals, D Cupissol, et al.
European Journal of Cancer (Oxford, England : 1990)|September 3, 2004
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancerE Guardiola, F Peyrade, L Chaigneau, et al.
Pageof 8